Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
EOLS Stock Chart & Stats
$6.98
-$0.47(-4.38%)
At close: 4:00 PM EST
$6.98
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$5.71 - $17.12
Previous CloseN/A
Volume344.54K
Average Volume (3M)1.60M
Market Cap
$452.44M
Enterprise Value$508.79M
Total Cash (Recent Filing)$43.52M
Total Debt (Recent Filing)$154.89M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Mar 11, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding64,819,786
10 Day Avg. Volume1,728,009
30 Day Avg. Volume1,602,590
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)123.99
Price to Sales (P/S)2.57
P/FCF Ratio-35.16
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit2.70
Enterprise Value/Ebitda-17.36
Forecast
1Y Price Target
$19.50Price Target Upside179.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$298.52M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement reaffirmed its net revenue guidance for 2025, expecting between $295 million and $305 million given solidifying performance for Jeuveau and a strong launch for Evolysse.
Product StrengthJeuveau's 3Q25 performance bucked the usual summer seasonal trends and continued toxin market weakness, helping to erase some growth concerns.
Profitability OutlookManagement remains confident in achieving profitability, with a projected non-GAAP operating income of $5 million to $7 million in 4Q.
Bears Say
Investor UncertaintyManagement's 2028 revenue 'target' of $700M is an overhang, creating uncertainty among investors.
Market ConditionsContinuing macro pressures and negative consumer sentiment are weighing down on the aesthetics market, restricting growth of toxins and fillers.
Sales ImpactNear-term market softness is likely to continue impacting Jeuveau's sales.
Evolus News
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $5.71 and its highest was $17.12 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $452.44M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is Mar 11, 2026 which is in 103 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Nov 05, 2025. The company reported -$0.132 earnings per share for the quarter, beating the consensus estimate of -$0.163 by $0.031.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is 0.05.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 64,819,786 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of -$0.132 in its last earnings report, beating expectations of -$0.163. Following the earnings report the stock price went up 5.433%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in EOLS
Evolus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.50 (179.37% Upside)
$19.50 (179.37% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 29.1%
Last 30 Days ▲ 29.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc. is a performance-based aesthetic company focused on delivering innovative, non-surgical aesthetic solutions to enhance beauty and confidence. The company primarily operates in the medical aesthetics sector and offers products designed to address the needs of consumers and healthcare providers. Evolus is known for its flagship product, Jeuveau, a botulinum toxin type A injectable treatment aimed at reducing the appearance of glabellar lines, commonly known as frown lines. The company focuses on providing advanced aesthetic technologies that cater to a growing market of consumers seeking non-invasive aesthetic treatments.
EOLS Company Deck
EOLS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong growth in consumer engagement, successful product launches, and international expansion, despite facing macroeconomic challenges and tariff uncertainties. Evolus demonstrates resilience and strategic adaptation, positioning for continued growth.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$19.50
▲(179.37% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.26% Insiders
10.02% Mutual Funds
43.63% Other Institutional Investors
31.54% Public Companies and
Individual Investors